B-intervention	0	8	Complete
I-intervention	9	17	hormonal
I-intervention	18	26	blockade
O	27	33	versus
B-control	34	44	epirubicin
I-control	44	45	-
I-control	45	50	based
I-control	51	63	chemotherapy
O	64	66	in
O	67	80	premenopausal
O	80	81	,
O	82	85	one
O	86	88	to
O	89	94	three
O	95	99	node
O	99	100	-
O	100	108	positive
O	108	109	,
O	110	113	and
O	114	121	hormone
O	121	122	-
O	122	130	receptor
O	131	139	positive
O	139	140	,
O	141	146	early
O	147	153	breast
O	154	160	cancer
O	161	169	patients
O	169	170	:
O	171	172	7
O	172	173	-
O	173	177	year
O	178	184	follow
O	184	185	-
O	185	187	up
O	188	195	results
O	196	198	of
B-location	199	205	French
O	206	214	Adjuvant
O	215	220	Study
O	221	226	Group
O	227	229	06
O	230	240	randomised
O	241	246	trial
O	246	247	.

O	248	251	The
O	252	259	purpose
O	260	262	of
O	263	267	this
O	268	273	study
O	274	277	was
O	278	280	to
O	281	290	determine
O	291	298	optimal
O	299	307	adjuvant
O	308	315	therapy
O	316	323	between
O	324	332	complete
O	333	341	hormonal
O	342	350	blockade
O	351	353	in
B-eligibility	354	367	premenopausal
I-eligibility	368	376	patients
I-eligibility	377	381	with
I-eligibility	382	389	hormone
I-eligibility	390	398	receptor
I-eligibility	399	407	positive
I-eligibility	408	414	breast
I-eligibility	415	421	cancer
I-eligibility	422	425	and
I-eligibility	426	429	one
I-eligibility	430	432	to
I-eligibility	433	438	three
I-eligibility	439	447	positive
I-eligibility	448	453	nodes
O	453	454	.

O	455	457	We
O	458	468	randomised
B-total-participants	469	472	333
O	473	481	patients
O	482	484	to
O	485	492	receive
O	493	499	either
O	500	504	LHRH
O	505	512	agonist
O	513	514	(
O	514	525	triptorelin
O	526	527	3
O	527	528	.
O	528	530	75
O	531	533	mg
O	534	535	i
O	535	536	.
O	537	538	m
O	538	539	.
O	539	540	,
O	541	548	monthly
O	548	549	)
O	550	554	plus
O	555	564	tamoxifen
O	565	567	30
O	568	570	mg
O	570	571	/
O	571	574	day
O	575	578	for
O	579	580	3
O	581	586	years
O	587	588	(
O	588	591	TAM
O	591	592	-
O	592	597	LHRHa
O	597	598	,
O	599	600	n
O	600	601	=
B-intervention-participants	601	604	164
O	604	605	)
O	605	606	,
O	607	609	or
O	610	622	fluorouracil
O	623	626	500
O	627	629	mg
O	629	630	/
O	630	632	m2
O	632	633	,
O	634	644	epirubicin
O	645	647	50
O	648	650	mg
O	650	651	/
O	651	653	m2
O	654	657	and
O	658	674	cyclophosphamide
O	675	678	500
O	679	681	mg
O	681	682	/
O	682	684	m2
O	685	690	every
O	691	693	21
O	694	698	days
O	699	702	for
O	703	706	six
O	707	713	cycles
O	713	714	,
O	715	722	without
O	723	726	any
O	727	735	hormonal
O	736	745	treatment
O	746	747	(
O	747	752	FEC50
O	752	753	,
O	754	755	n
O	755	756	=
B-control-participants	756	759	169
O	759	760	)
O	760	761	.

O	762	765	The
B-outcome	766	767	7
I-outcome	767	768	-
I-outcome	768	772	year
I-outcome	773	780	disease
I-outcome	780	781	-
I-outcome	781	785	free
I-outcome	786	794	survival
I-outcome	795	796	(
I-outcome	796	799	DFS
I-outcome	799	800	)
O	801	804	was
B-iv-bin-percent	805	807	76
I-iv-bin-percent	807	808	%
O	809	813	with
O	814	817	TAM
O	817	818	-
O	818	823	LHRHa
O	823	824	,
O	825	828	and
B-cv-bin-percent	829	831	72
I-cv-bin-percent	831	832	%
O	833	837	with
O	838	843	FEC50
O	844	845	(
O	845	846	P
O	846	847	=
O	847	848	0
O	848	849	.
O	849	851	13
O	851	852	)
O	852	853	.

O	854	857	The
B-outcome	858	859	7
I-outcome	859	860	-
I-outcome	860	864	year
I-outcome	865	872	overall
I-outcome	873	881	survival
I-outcome	882	883	(
I-outcome	883	885	OS
I-outcome	885	886	)
O	887	890	was
B-iv-bin-percent	891	893	91
I-iv-bin-percent	893	894	%
O	895	898	and
B-cv-bin-percent	899	901	88
I-cv-bin-percent	901	902	%
O	902	903	,
O	904	916	respectively
O	917	918	(
O	918	919	P
O	919	920	=
O	920	921	0
O	921	922	.
O	922	924	20
O	924	925	)
O	925	926	.

O	927	930	The
O	931	943	multivariate
O	944	952	analysis
O	953	962	confirmed
O	963	967	that
O	968	972	both
O	973	983	treatments
O	984	988	were
O	989	992	not
O	993	1002	different
O	1003	1006	for
O	1007	1010	DFS
O	1011	1014	and
O	1015	1017	OS
O	1018	1019	(
O	1019	1020	P
O	1020	1021	=
O	1021	1022	0
O	1022	1023	.
O	1023	1025	83
O	1026	1029	and
O	1030	1031	P
O	1031	1032	=
O	1032	1033	0
O	1033	1034	.
O	1034	1036	41
O	1036	1037	,
O	1038	1050	respectively
O	1050	1051	)
O	1051	1052	.

B-outcome	1053	1064	Amenorrhoea
O	1065	1073	occurred
O	1074	1076	in
B-cv-bin-percent	1077	1079	64
I-cv-bin-percent	1079	1080	%
O	1081	1083	of
O	1084	1092	patients
O	1093	1100	treated
O	1101	1105	with
O	1106	1111	FEC50
O	1111	1112	;
O	1113	1115	it
O	1116	1119	was
O	1120	1129	temporary
O	1130	1132	in
B-iv-bin-percent	1133	1135	58
I-iv-bin-percent	1135	1136	%
O	1137	1139	of
O	1140	1145	cases
O	1146	1151	after
O	1152	1166	hormonotherapy
O	1167	1170	and
O	1171	1173	in
B-cv-bin-percent	1174	1176	31
I-cv-bin-percent	1176	1177	%
O	1178	1183	after
O	1184	1196	chemotherapy
O	1196	1197	.

O	1198	1200	In
O	1201	1213	intermediate
O	1213	1214	-
O	1214	1218	risk
O	1219	1225	breast
O	1226	1232	cancer
O	1232	1233	,
O	1234	1242	complete
O	1243	1251	hormonal
O	1252	1260	blockade
O	1261	1264	and
O	1265	1277	chemotherapy
O	1278	1286	provided
O	1287	1294	similar
O	1295	1303	outcomes
O	1303	1304	.

O	1305	1313	Hormonal
O	1314	1323	treatment
O	1324	1326	is
O	1327	1329	an
O	1330	1341	alternative
O	1342	1344	to
O	1345	1357	chemotherapy
O	1358	1360	in
O	1361	1368	hormone
O	1368	1369	-
O	1369	1378	sensitive
O	1379	1387	patients
O	1387	1388	,
O	1389	1400	considering
O	1401	1404	the
O	1405	1415	preference
O	1416	1418	of
O	1419	1427	patients
O	1428	1430	in
O	1431	1436	terms
O	1437	1439	of
O	1440	1447	quality
O	1448	1450	of
O	1451	1455	life
O	1455	1456	.
